 Influence chemotherapy administration monocyte activation liposomal muramyl phosphatidylethanolamine children osteosarcoma purpose studies chemotherapy ability peripheral blood monocytes patients osteosarcoma liposome-encapsulated activating agent muramyl tripeptide phosphatidylethanolamine L-MTP-PE preparation adjuvant therapy protocol L-MTP-PE chemotherapy treatment primary osteosarcoma majority patients current adjuvant chemotherapy chemotherapy important L-MTP-PE chemotherapy treatment course chemotherapy cycles tumoricidal properties monocytes patients osteosarcoma L-MTP-PE levels equal normal control monocytes intrinsic monocyte defect Single-agent chemotherapy consisting cisplatin CPD high-dose methotrexate MTX Cytoxan CTX cyclophosphamide Bristol-Myers Co Evansville IN Adriamycin ADR doxorubicin Adria Columbus OH activation process suggestion enhanced activation potential administration ADR ADR CTX day profound suppression monocyte activation suppressed function normal weeks postcombination therapy L-MTP-PE ADR CPD MTX CTX single agents ADR L-MTP-PE effective combination contrast use L-MTP-PE ADR CTX